登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000985 证券简称：大庆华科 公告编号：2026005 大庆华科股份有限公司关于召开2026年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 6、会议的股权登记日：2026年02月13日 7、出席对象： 大庆华科股份有限公司（以下简称"公司"）定于2026年2月27日（星期五）14:30召开2026年第一次临时 股东会（以下简称"本次股东会"）。会议通知公告（公告编号2026004）已于2026年1月30日在巨潮资讯 网(http://www.cninfo.com.cn) 、《中国证券报》及《上海证券报》上发布。本次股东会将采用现场投票 和网络投票相结合的方式，现对公司召开本次股东会再次提示公告如下： 一、召开会议的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等法律、行政法规、部门 ...

证券代码：000985 证券简称：大庆华科 公告编号：2026005 大庆华科股份有限公司关于召开 2026 年第一次临时股东会的提示性公告 4、会议时间： （1）现场会议时间：2026 年 02 月 27 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具 体时间为 2026 年 02 月 27 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2026 年 02 月 27 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 大庆华科股份有限公司（以下简称"公司"）定于 2026 年 2 月 27 日（星期五）14:30 召开 2026 年第一次临时股东会（以下简称"本次 股东会"）。会议通知公告（公告编号 2026004）已于 2026 年 1 月 30 日 在巨潮资讯网(http://www.cninfo.com.cn) 、《中国证券报》及《上 海证券报》上发布。本次股东会 ...

公司将于2026年2月27日召开2026年第一次临时股东会，审议修订《公司章程》的议案，该议案旨在明 确法定代表人的选举方式，由董事会以全体董事过半数选举产生或更换。此次会议采取现场与网络投票 相结合的方式，股权登记日为2026年2月13日。 经济观察网 大庆华科股份有限公司将召开临时股东会审议修订《公司章程》议案，并已披露2025年度 业绩预告。 高管变动 此外，市场分析提及重组预期，但此为基于公开信息的推测，并非公司官方确认事件。 以上内容基于公开资料整理，不构成投资建议。 业绩经营情况 公司已于2026年1月29日发布2025年度业绩预告，预计扣除非经常性损益后的净利润盈利350万元至450 万元，同比下降70.93%至77.39%，最终数据将以2025年年度报告为准。年度报告的具体发布日期尚未 公告，但通常会在2026年初披露。 ...

Market Overview - The refining and trading sector experienced a decline of 0.77% on February 3, with ST Shenhua leading the drop [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Notable gainers in the refining and trading sector included: - Runbei Hangke (001316) with a closing price of 56.33, up 10.00% [1] - Heshun Petroleum (603353) at 38.65, up 5.83% [1] - Tongkun Co. (601233) at 20.99, up 4.48% [1] - Conversely, ST Shenhua (000698) saw a decline of 3.04%, closing at 3.83 [2] Trading Volume and Capital Flow - The total trading volume for the refining and trading sector showed a net outflow of 79.01 million yuan from main funds, with retail investors contributing a net inflow of 244 million yuan [2] - The capital flow for individual stocks indicated that: - Guanghui Energy (600256) had a net inflow of 48.13 million yuan from main funds [3] - China Petroleum (601857) recorded a net inflow of 45.05 million yuan from main funds [3] - Runbei Hangke (001316) had a net inflow of 46.34 million yuan from main funds [3]

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

Group 1 - The company Daqing Huake expects a net profit attributable to shareholders of 6 million to 7.8 million yuan for 2025, representing a year-on-year decline of 47.25% to 59.42% [1] - The basic earnings per share are projected to be between 0.046 yuan and 0.06 yuan [1] - The main reasons for the profit decline include a general downward trend in international oil prices, lack of significant improvement in product market demand, and reduced profit margins for chemical products [1] Group 2 - The increase in deferred income tax expenses is significantly impacted by temporary differences in accounting and tax laws [1] - The overall market conditions have led to a substantial year-on-year decrease in the company's net profit [1]

Core Viewpoint - The company Daqing Huake expects a significant decline in net profit for the fiscal year 2025, projecting a range of 6 million to 7.8 million yuan, which represents a year-on-year decrease of 59.42% to 47.25% compared to the previous year's net profit of 14.7854 million yuan [1] Group 1 - The decline in net profit is attributed to the overall downward trend in international crude oil prices and a lack of significant improvement in product market demand [1] - The profit margin for the company's chemical products has decreased, contributing to the anticipated drop in net profit [1] - A substantial increase in deferred income tax expenses due to temporary differences in accounting and tax laws has also impacted the net profit negatively [1]

Core Viewpoint - Daqing Huake is forecasting a significant decline in net profit for the year 2025, primarily due to falling international oil prices and reduced profit margins in chemical products [1] Financial Performance - The company expects a net profit attributable to shareholders of 6 million to 7.8 million yuan for 2025, representing a year-on-year decrease of 47.25% to 59.42% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 3.5 million and 4.5 million yuan, indicating a year-on-year decline of 70.93% to 77.39% [1] Market Conditions - The overall international oil price has been on a downward trend, which has not seen a significant improvement in product market demand [1] - The reduction in profit margins for the company's chemical products is attributed to these market conditions [1] Tax Implications - A significant increase in deferred income tax expenses is noted due to temporary differences in accounting and tax laws, contributing to the larger year-on-year decline in net profit [1]

Profit Forecast - The estimated net profit attributable to shareholders for 2025 is projected to be between 6 million and 7.8 million yuan, representing a decline of 47.25% to 59.42% compared to the previous year's profit of 14.7854 million yuan[3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 3.5 million and 4.5 million yuan, reflecting a decrease of 70.93% to 77.39% from the previous year's figure of 15.4778 million yuan[3]. - The basic earnings per share is forecasted to be between 0.046 yuan and 0.060 yuan, down from 0.1141 yuan per share in the previous year[3]. Factors Affecting Profit - The decline in profit is attributed to the overall downward trend in international crude oil prices and a lack of significant improvement in product market demand, leading to reduced profit margins for chemical products[5]. - The increase in deferred income tax expenses due to temporary differences in accounting and tax laws has significantly impacted net profit[6]. Caution and Audit - The financial data in this earnings forecast has not been audited by registered accountants, and there may be discrepancies with the final data disclosed in the 2025 annual report[4]. - The company emphasizes the importance of cautious decision-making and awareness of investment risks based on the preliminary nature of the earnings forecast[7].

Group 1 - Daqing Huake announced the resignation of Ms. Cui Fengling as the securities affairs representative due to work changes, effective immediately upon delivery to the board of directors [1] - The company has appointed Mr. Zhang Xia as the new securities affairs representative to assist the board secretary in fulfilling responsibilities [1] Group 2 - The investigation into the "Jie Wo Rui" redemption crisis on the Shuibei Gold platform revealed a 40-fold leverage bet, indicating that the platform incurs losses as gold prices rise [1] - Investors reported that the proposed redemption plan offered only 20% of the principal, which they found unacceptable [1]